refill of liquid on tubesPhoto by Louis Reed

Plenary Presentations Highlight Tagrisso and Imfinzi’s Potential in Early Lung Cancer

London, UK – This Tuesday, AstraZeneca confirmed that it is set to present new data across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4, 2024. More than 100 abstracts will feature 25 approved and potential new medicines across AstraZeneca’s diverse oncology portfolio. The company will deliver two late-breaking plenary presentations, a special late-breaking abstract session, and 15 oral presentations.

Key Highlights:

  1. LAURA Phase III Trial:
    • Tagrisso (osimertinib) in unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). Plenary LBA4 will present significant findings on progression-free survival (PFS), highlighting Tagrisso’s potential in improving patient outcomes.
  2. ADRIATIC Phase III Trial:
    • Imfinzi (durvalumab) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent CRT (cCRT). Plenary LBA5 will showcase results demonstrating Imfinzi’s significant overall survival (OS) and PFS benefits.
  3. DESTINY-Breast06 Phase III Trial:
    • Enhertu (trastuzumab deruxtecan) in patients with metastatic hormone receptor (HR)-positive HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. The late-breaking abstract (LBA1000) will reveal Enhertu’s promising efficacy and potential to improve PFS in this broader patient population.

Additionally, AstraZeneca will present a first-in-human, investigator-initiated trial of C-CAR031, a novel autologous armoured Glypican 3 (GPC3) targeting chimeric antigen receptor T cell (CAR-T) therapy, based on AZD5851, in patients with liver cancer. This trial (Rapid Oral Abstract 4019) highlights AstraZeneca’s innovative approach in cell therapy.

AstraZeneca’s extensive presence at ASCO 2024 underscores its commitment to advancing cancer treatment and improving patient outcomes. The presentations reflect the company’s continuous efforts to push the boundaries of oncology with its innovative therapies and robust clinical research.

About AstraZeneca: AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner